Howard Lazarus - 17 Nov 2026 Form 4 Insider Report for Avalyn Pharma Inc. (AVLN)

SEC form
4
Accepted by SEC
19 Nov 2026, 16:42:35 UTC
Prior SEC filing
29 Apr 2026
Source filing
View source filing
Filing notes and source

Key filing fact

Howard Lazarus filed Form 4 for Avalyn Pharma Inc. (AVLN) on 19 Nov 2026.

Key facts

  • This page summarizes Howard Lazarus's Form 4 filing for Avalyn Pharma Inc. (AVLN).
  • 5 reported transactions and 1 derivative row are listed below.
  • Accepted by SEC: 19 Nov 2026, 16:42.

Change

  • Previous filing in this sequence was filed on 29 Apr 2026.
  • Current net transaction value: -$371,027.

Research use

  • This tells you what this filing adds before you inspect full transaction and derivative tables.
  • You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reporting Owners (1)

CIK 0002127626 Primary reporting owner

Lazarus Howard

Relationship
Chief Medical Officer

Reported non-derivative transactions

Shares, units, or other non-derivative securities reported in this filing.

AVLN transaction

Common Stock

Options Exercise

Transaction value
Shares
+13,300
Change %
Price
$4.62*
Shares after
13,300
Date
17 Nov 2026
Ownership
Direct
Footnotes
F1
AVLN transaction

Common Stock

Sale

Transaction value
-$306,441
Shares
-11,023
Change %
-83%
Price
$27.80
Shares after
2,277
Date
17 Nov 2026
Ownership
Direct
Footnotes
F1, F2
AVLN transaction

Common Stock

Sale

Transaction value
-$58,410
Shares
-2,066
Change %
-91%
Price
$28.27
Shares after
211
Date
17 Nov 2026
Ownership
Direct
Footnotes
F1, F3
AVLN transaction

Common Stock

Sale

Transaction value
-$6,176
Shares
-211
Change %
-100%
Price
$29.27
Shares after
0
Date
17 Nov 2026
Ownership
Direct
Footnotes
F1, F4

Reported derivative securities

Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.

AVLN transaction Derivative

Stock Option (Right to Buy)

Options Exercise

Transaction value
Shares
-13,300
Change %
-4.9%
Price
$0.000000*
Shares after
257,198
Date
17 Nov 2026
Ownership
Direct
Underlying class
Common Stock
Underlying amount
13,300
Exercise price
$4.62
Footnotes
F1, F5
* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Rule 10b5-1 trading plan

These transactions were reported as open-market trades under a Rule 10b5-1 plan. The plan lets an insider set trading instructions in advance, which can reduce the risk of trading while in possession of material nonpublic information.

Original filing language: transaction made pursuant to a contract, instruction, or written plan intended to satisfy Rule 10b5-1(c).

Explanation of responses 5 footnotes

Footnote F1

These transactions were effected by the Reporting Person pursuant to a Rule 10b5-1 trading plan adopted on July 30, 2026.

Footnote F2

The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $27.11 to $28.10, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price at which the transactions were effected.

Footnote F3

The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $28.11 to $29.03, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price at which the transactions were effected.

Footnote F4

The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $29.13 to $29.37, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price at which the transactions were effected.

Footnote F5

25% of the shares underlying this option vested and became exercisable on August 7, 2024, with the remaining 75% vesting in thirty-six (36) substantially equal monthly installments thereafter, subject to the Reporting Person's continued service on each such vesting date.

We use cookies and similar technologies to provide certain features, enhance the user experience and, if you allow them, measure engagement and deliver advertising. Analytics and marketing storage stay off until you grant consent. By clicking on "Agree and continue", you declare your consent to the use of the selected optional cookies. Manage preferences to update or revoke optional consent for future visits. For more information, see our Privacy Policy .